title: Molecular profiling of platinum resistant ovarian cancer: use of the model in clinical practice.
authors.forename: Olivier
authors.initials: O
authors.lastname: Gevaert
authors.forename: Nathalie
authors.initials: N
authors.lastname: Pochet
authors.forename: Frank
authors.initials: F
authors.lastname: De Smet
authors.forename: Toon
authors.initials: T
authors.lastname: Van Gorp
authors.forename: Bart
authors.initials: B
authors.lastname: De Moor
authors.forename: Dirk
authors.initials: D
authors.lastname: Timmerman
authors.forename: Frédéric
authors.initials: F
authors.lastname: Amant
authors.forename: Ignace
authors.initials: I
authors.lastname: Vergote
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D002945:Cisplatin